Annonce • May 21
Prostatype Genomics AB (publ), Annual General Meeting, Jun 22, 2026 Prostatype Genomics AB (publ), Annual General Meeting, Jun 22, 2026, at 15:00 W. Europe Standard Time. Location: augustendalsvagen 20, nacka strand, Sweden Reported Earnings • Mar 02
Full year 2025 earnings released Full year 2025 results: Net loss: kr44.5m (loss widened 8.4% from FY 2024). New Risk • Feb 09
New minor risk - Financial data availability The company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2025. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr41m free cash flow). Share price has been highly volatile over the past 3 months (34% average weekly change). Earnings have declined by 28% per year over the past 5 years. Shareholders have been substantially diluted in the past year (over 7x increase in shares outstanding). Revenue is less than US$1m (kr715k revenue, or US$79k). Market cap is less than US$10m (kr84.6m market cap, or US$9.39m). Minor Risk Latest financial reports are more than 6 months old (reported June 2025 fiscal period end). Annonce • Jan 09
Prostatype Genomics U.S. Validation Study by Veterans Affairs (Va) Is Published Prostatype Genomics announced that the study performed in USA under the leadership of professor Stephen Freedland at Department of Urology at Cedars-Sinai, and in association with the Durham Veteran Affairs Healthcare System, has been accepted and is published in the medical journal Prostate Cancer and Prostatic Diseases Veterans Affairs is one of the world's largest integrated health care systems where Cedars-Sinai is ranked among the top 10 most influential hospitals in USA. The study includes a diverse patient population, with a significant proportion of African American patients, which is crucial for ensuring the clinical utility of the test across a broad demographic setting. In summary the study results shows that Prostatype has a strong and significant predictive ability to identify the men that really has a high risk of dying from prostate cancer which is the type of clinical information that doctors and health care payers are looking for. Furthermore, also seen in other published studies, Prostatype significantly outperforms existing clinical prognostic tools adding additional clinical benefit for patients, doctors and health care providers. Notably, no significant difference was observed in the test's performance between African American and Caucasian patients, reinforcing Prostatype's robustness and reliability across different patient groups. Recent Insider Transactions • Oct 09
Independent Chairman of the Board recently bought kr98k worth of stock On the 3rd of October, Anders Lundberg bought around 188k shares on-market at roughly kr0.52 per share. This transaction amounted to less than 1% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. This was Anders' only on-market trade for the last 12 months. Reported Earnings • Jul 25
First half 2025 earnings released: kr1.42 loss per share (vs kr31.07 loss in 1H 2024) First half 2025 results: kr1.42 loss per share. Net loss: kr23.9m (loss widened 22% from 1H 2024). Annonce • May 16
Prostatype Genomics AB (Publ) Announces Johan Waldhe Was Not Re-Elects, as He Had Declares That He Was Not Available for Re-Election Prostatype Genomics AB (publ) at its annual general meeting held on 15 May 2025, approved Johan Waldhe was not re-elected, as he had declared that he was not available for re-election. Annonce • Apr 16
Prostatype Genomics AB (publ), Annual General Meeting, May 15, 2025 Prostatype Genomics AB (publ), Annual General Meeting, May 15, 2025, at 15:00 W. Europe Standard Time. Location: at augustendalsvagen 20, 131 52 nacka strand, Sweden Annonce • Apr 15
Prostatype Genomics AB (Publ) Announces Johan Waldhe Not Available for Re-Election Prostatype Genomics AB (publ) announced that Johan Waldhe has declared that he is not available for re-election due to other commitments. Annonce • Mar 31
Prostatype Genomics Announces Positive Preliminary Results for Primary Endpoints in U.S. Study with Prostatype Prostatype Genomics announced that preliminary results from the study conducted in the United States in collaboration with leading institutions shows promising results. Prostatype is a genomic test designed to improve risk stratification of patients diagnosed with non-metastatic prostate cancer. The study has a diverse patient population, with a significant proportion of African American patients, which is crucial for ensuring the clinical utility of the test in a patient population with multiple ethnicities. Reported Earnings • Feb 15
Full year 2024 earnings released Full year 2024 results: Net loss: kr41.1m (flat on FY 2023). Annonce • Feb 13
Prostatype Genomics AB Submits Supplementary Answers in the Final Phase of its Medicare Application for Reimbursement in the United States Prostatype Genomics AB announced that the company has compiled and submitted supplementary answers in the final phase of its Medicare application to get the prognostic genomic test Prostatype®? approved for reimbursement in the United States. The compilation has been conducted in an efficient manner together with external partners in Sweden and the United States to create optimal conditions to complete the application process and get Prostatype®? approval for reimbursement in the near future. In the end of September, Prostatype Genomics submitted its application to Medicare (within the MolDX program) to get the genomic test Prostatype®®?, which is used for risk classification of established prostate cancer, approved for reimbursement in the United United States. The application process is facilitated by the fact that the company is applying to include Prostatype®? in an already existing category for reimbursement with an established payment level. On January 3, the company announced that the application had reached its final phase, as a limited number of supplementary questions had been received following Medicare's processing of the full application. These questions were in line with what the company expected, and it has thus been possible to compile the answers in an efficient manner. To make sure that Medicare receives precisely the information requested, as clearly as possible, the company is collaborating with external experts in both Sweden and the United States. New Risk • Feb 11
New minor risk - Financial data availability The company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2024. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr47m free cash flow). Share price has been highly volatile over the past 3 months (16% average weekly change). Earnings have declined by 34% per year over the past 5 years. Shareholders have been substantially diluted in the past year (over 7x increase in shares outstanding). Revenue is less than US$1m (kr4.1m revenue, or US$377k). Market cap is less than US$10m (kr58.1m market cap, or US$5.32m). Minor Risk Latest financial reports are more than 6 months old (reported June 2024 fiscal period end). Annonce • Jan 03
Prostatype Genomics Medicare Reimbursement Application in the United States Is Now in Its Final Phase Prostatype Genomics AB announced that the company's application for inclusion of the genomic test Prostatype in the federal U.S. healthcare program Medicare's reimbursement system is now in its final phase. A limited number of supplementary questions have been received, and the company is working on compiling the answers which will be submitted to Medicare shortly. The company has thus taken a major step towards completing the application process and getting Prostatype approved for reimbursement in the near future. Prostatype Genomics submitted its application to Medicare (within the MolDX program) according to plan in September 2024. The first supplementary question was received shortly after the application was submitted, but it has taken up until now for the whole application to be processed followed by a more complete response with supplementary questions. The type of supplementary questions received is in line with what the company has been expecting, which means that the answers can be rapidly compiled and sent to Medicare. The company now looks forward to an exciting and value-driving 2025, with a strong focus on commercial activities in the United States, combined with continued commercial activities in selected EMEA markets such as Italy, Spain and Taiwan. Recent Insider Transactions • Sep 29
Independent Director recently bought kr821k worth of stock On the 23rd of September, Michael Haggman bought around 41m shares on-market at roughly kr0.02 per share. This transaction increased Michael's direct individual holding by 65x at the time of the trade. This was the largest purchase by an insider in the last 3 months. Insiders have collectively bought kr780k more in shares than they have sold in the last 12 months. Annonce • Sep 04
Prostatype Genomics AB (publ) has completed a Composite Units Offering in the amount of SEK 39.535402 million. Prostatype Genomics AB (publ) has completed a Composite Units Offering in the amount of SEK 39.535402 million.
Security Name: Units
Security Type: Equity/Derivative Unit
Securities Offered: 790,708,046
Price\Range: SEK 0.05
Transaction Features: Rights Offering Reported Earnings • Jul 30
First half 2024 earnings released: kr0.031 loss per share (vs kr0.37 loss in 1H 2023) First half 2024 results: kr0.031 loss per share (improved from kr0.37 loss in 1H 2023). Revenue: kr1.45m (up 37% from 1H 2023). Net loss: kr19.7m (loss narrowed 4.3% from 1H 2023). Annonce • May 24
Prostatype Genomics AB (Publ) Elects Johan Waldhe as New Member of the Board Prostatype Genomics AB (publ) at its annual general meeting held on 23 May 2024, Johan Waldhe was elected as new member of the board. Annonce • Apr 19
Prostatype Genomics Announces Very Strong Interim Results from Long-Term Follow-Up Study with Prostatype in Uppsala Prostatype Genomics AB announced that interim results from 180 of a total of approximately 500 patients in the ongoing long-term follow-up study at Akademiska University Hospital in Uppsala, Sweden, with the Company's genetic test Prostatype® show excellent accuracy for Prostatype® even after 20 years of follow-up time after diagnosis. None of the analysed patients classified as low risk by Prostatype® died from their prostate cancer during 20 years of follow-up time. The interim results from the Uppsala study, together with data from the ongoing US study with Prostatype® and data from other conducted studies, will be included in the Company's upcoming Medicare application in the United States with the aim to get Prostatype® approved for reimbursement in fourth quarter 2024. Complete interim data from the Uppsala study will be presented at the annual American Urological Association (AUA) conference in the United States in May 2024, one of the leading scientific conferences in the field of urology on a global level. The company's Medicare application to get Prostatype® approved for reimbursement in the United States, with expected submission in Q2-Q3 2024 and expected approval in fourth quarter 2024, will include data from the ongoing US study, as well as data from other studies including the Uppsala study. The United States is the world's largest market for gene testing of patients with established prostate cancer, with current annual sales of approx. SEK 2 billion (USD 200 million), and the Company estimates the total market potential in the United States to be approx. SEK 6 billion (USD 600 million) per year. The genetic test Prostatype® is used as a supplementary guidance for urologists when selecting treatment type for patients diagnosed with prostate cancer. Prostate cancer affects around one in eight men, of which approx. 50-90% undergo radical treatment. According to the Company's assessment, about a third of these radical treatments could be avoided or postponed if the patients were correctly risk-classified, and there is thus a great need for improved guidance when deciding on treatment type. Reported Earnings • Feb 16
Full year 2023 earnings released Full year 2023 results: Revenue: kr3.79m (up 455% from FY 2022). Net loss: kr41.4m (loss widened 43% from FY 2022). New Risk • Jan 09
New major risk - Revenue and earnings growth Earnings have declined by 28% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr37m free cash flow). Share price has been highly volatile over the past 3 months (50% average weekly change). Earnings have declined by 28% per year over the past 5 years. Shareholders have been substantially diluted in the past year (423% increase in shares outstanding). Revenue is less than US$1m (kr861k revenue, or US$84k). Market cap is less than US$10m (kr13.0m market cap, or US$1.26m). Annonce • Dec 22
Prostatype Genomics AB (publ) Announces Long Term Follow Up Study At Akademiska University Hospital, Uppsala, to Be Presented At EAU-Meeting, May 2024: Indicates New Area of Use for Prostatype® Prostatype Genomics AB (publ) has in collaboration with Akademiska University Hospital during 2023 initiated a comprehensive study in patients with localized prostate cancer over the course of 25 years. The study has been submitted to the prestigious and largest urology conference in Europe, the 39th Annual EAU (European Association of Urology) Congress. The congress received 5651 abstracts of various kinds, the highest number in many years. The company announced that the new study from Akademiska University Hospital has been selected to present at the EAU Congress in Paris in May, 2024. The interim results, after having analyzed approximately 100 patients out of a total cohort of approximately 500 patients, indicates that the usage of Prostatype® can aid clinicians and patients to make decisions on surveillance versus treatment, rather than having to rely on clinical indicators alone. The results reveals that the test provides an accurate assessment of the risk of long-term prostate cancer-specific mortality, or PCSM, for patients with localized prostate cancer. These 25-year findings suggest that Prostatype® can be used as an indicator of long-term risk of prostate cancer-specific mortality. In the study, researchers at the Akademiska University Hospital analyzes the association between the Prostatype®-result and long-term oncological outcomes following radical prostatectomy in a stratified cohort sample of 500 patients who were treated between 1991 and 2001. The study is expected to be fully completed during the final quarter of 2024. The company is anticipating that the study will be published in a scientific journal later next year which will help to expand the fields of usage of Prostatype® and its recommendation by the American NCCN and the European EAU guidelines for men who've been diagnosed with very low-, low-, or intermediate-risk disease, to determine whether their disease can be conservatively managed through active surveillance rather than treated with definitive surgery or radiation therapy. Annonce • Nov 07
Prostatype Genomics AB (publ) Announces Henrik Nilsson to Leave the Board of Directors Prematurely Prostatype Genomics AB (publ) announced that Henrik Nilsson has announced to the nomination committee that he wish to leave the board of directors prematurely due to family reasons. Therefore, the nomination committee proposes that Henrik Nilsson is replaced by Jörgen Dahlström. At the annual general meeting on 1 June 2023, it was resolved regarding remuneration for the board of directors. No changes are proposed with respect to this resolution. However, the remuneration for the period until the next annual general meeting (2024) will be proportionate to the time Jörgen Dahlström holds the position.Assuming Jörgen Dahlström is elected as member of the board of directors, the Company's board will consist of the following persons: Anders Lundberg (Chairman), Michael Häggman, Mattias Prage, Håkan Englund and Jörgen Dahlström. Annonce • Nov 01
Prostatype Genomics Appoints Anders Koch as New CFO Anders Koch has been appointed as the new CFO for Prostatype Genomics and takes up the position with immediate effect. Anders' extensive experience in streamlining and optimizing operations during growth on an international level will be a great asset for Prostatype Genomics. Anders Koch has over 25 years of experience from positions in finance and leadership, most recently from an interim assignment at Goodbye Kansas Group AB (publ), also listed on Nasdaq First North. Anders Koch succeeds Michael af Winklerfelt, who remains in the company during a handover period. Annonce • Oct 31
Prostatype Genomics AB (Publ) Announces Updated Strategy and Implementation of Efficiency Programs in Prostatype Genomics Prostatype Genomics AB announced that during 2022 and 2023, Prostatype Genomics has introduced Prostatype®?, the company's prognostic gene test for prostate cancer, in European pilot markets and in Taiwan in parallel with a mapping of the market in the USA. Based on these experiences, the company can now specify the strategy moving forward which means: that the company continues to invest in attractive entry countries within Europe; that the company expands the business in Asia with Taiwan as a springboard; that the company implements a quick and cost-effective establishment in the American market. This will be achieved at the same time as an efficiency program is implemented, which means that running costs are reduced by approximately 30% (approximately SEK 9 million on an annual basis) without affecting sales and continued research. Prostatype Genomics has two main strategic areas of activity: commercial establishment and strengthening of Prostatype®?'s scientific basis in the form of external studies. Over the past two years, the company has systematically worked to map and evaluate various markets and approaches from a commercial perspective on site in various countries in order to identify whether the following criteria are met or can be met in the near future: Clinical acceptance of genetic testing in prostate cancer and confirmed clinical benefit; Market acceptance via clinics evaluating and starting to use Prostatype®? on a smaller scale. It is difficult to predict how a patient's prostate cancer should best be treated with conventional methods. The company have been able to establish that the clinical need for accurate biomarkers in diagnosed prostate cancer is very clear regardless of European country. The company has managed to achieve a high trial rate in clinics with strong results and the doctors are positive, which has shown that Prostatype®? fulfils a large and clear clinical need. Prostatype®? will be launched on the American market as a so-called LDT product (Laboratory Developed Test). The company thereby avoid a long, costly and uncertain FDA process. The company do not differ from American companies that provide similar products but use the same established approach. Furthermore, do not establish own laboratory in the USA but work with a "lab-in-lab" solution where the company uses an already existing infrastructure of a partner who holds the necessary permits and a so-called CLIA license. This ensures high flexibility for extensive sales in the US in a cost-effective manner. The US market for product is estimated to be worth approximately 600 MUSD annually. With a completed study in the USA, goal is for the product to achieve the attractiveness required to be able to switch up the business after Fourth Quarter 2024 via partnerships with major players in the industry on a global or regional basis either in the form of part ownership or commercial collaboration. This work has already started. As already mentioned, the company, based on the experiences gained during 2022 and 2023, has introduced an efficiency program. This program will lead to an annual reduction of current costs corresponding to SEK 9 million or approximately 30% of the total cost. The board's and management's joint assessment is that this can be implemented without the overall strategy or pace being affected, as resources are instead concentrated on the markets where the company see immediate potential. Work on continuous product development can continue at an unchanged level. Streamlining further frees up the resources needed for the company's primary focus, which is the American market. Annonce • Oct 26
Prostatype Genomics Announces New Multi-Centre Study in Spain Shows Very Strong Interim Results for Prostatype(R) Prostatype Genomics is currently conducting a study of 160 patients together with seven leading Spanish hospitals and the Spanish National Association of Urology. The initial results are very strong and show that approximately 60% of patients would have been reclassified if Prostatype had been used for prognostic and treatment decisions after diagnosis. In a new retrospective multicentre study with Prostatype(R) in Spain including 160 patients from a total of seven hospitals, coordinated by the Spanish National association of Urology, an interim analysis has been performed after three hospitals completed the results. The interim analysis shows that there is again strong evidence that Prostatype(R) provides important additional information that can change the treatment plan or actual treatment for prostate cancer patients initially classified as low or intermediate risk. The initial analysis indicates that the treatment plan can be changed in approximately as many as 60% of the cases if Prostatype(R) had been used after the established diagnosis. The study further indicates that Prostatype(R") can predict progression, i.e., the test can predict who needs curative treatment immediately upon diagnosis and who are not suitable for active monitoring. The interim analysis also shows that Prostatype(R), confirms the cases in which it may be appropriate to postpone curative treatment for some men with low-risk prostate cancer. In conclusion, the analysis shows that the patients who develop metastases and die due to prostate cancer are classified as high risk with Prostatype(R). at the time of diagnosis. New Risk • Oct 19
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Swedish stocks, typically moving 12% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr37m free cash flow). Share price has been highly volatile over the past 3 months (12% average weekly change). Shareholders have been substantially diluted in the past year (423% increase in shares outstanding). Revenue is less than US$1m (kr861k revenue, or US$79k). Market cap is less than US$10m (kr22.7m market cap, or US$2.07m). Minor Risk Currently unprofitable and not forecast to become profitable over next 2 years (kr11m net loss in 2 years). Annonce • Sep 05
Prostatype Genomics CFO Michael af Winklerfelt Leaving the Company Prostatype Genomics CFO Michael af Winklerfelt is leaving the company after three years. Michael will resign from his position as of December 4. The company has started the process of finding a replacement for the function as CFO. Reported Earnings • Aug 18
Second quarter 2023 earnings: Revenues miss analyst expectations Second quarter 2023 results: Net loss: kr10.1m (loss widened 37% from 2Q 2022). Revenue missed analyst estimates by 93%. Revenue is forecast to grow 114% p.a. on average during the next 3 years, compared to a 25% growth forecast for the Biotechs industry in Sweden. Annonce • Aug 18
Prostatype Genomics AB (Publ) Provides Revenue Guidance for the Third Quarter of 2023 Prostatype Genomics AB (publ) provided revenue guidance for the third quarter of 2023. The Company also projects that revenue growth will return to positive trend in the Third Quarter. Buying Opportunity • Jul 10
Now 26% undervalued after recent price drop Over the last 90 days, the stock is down 14%. The fair value is estimated to be kr0.51, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue is forecast to grow by 2,779% in 2 years. Earnings is forecast to grow by 36% in the next 2 years. Annonce • Jun 21
Prostatype Genomics AB Appoints Gerald Andriole as Chief Medical Officer Prostatype Genomics AB announced that Professor Gerald Andriole has been appointed as global Chief Medical Officer at Prostatype Genomics. With more than 35 years in urology, Professor Andriole brings a wealth of experience and expertise to Prostatype Genomics as the company works towards commercializing the Prostatype® test in the United States and globally. Gerald L. Andriole, Jr., MD, was most recently Professor in the Department of Urology and Director of the Brady Urological Institute in the National Capital Region of Johns Hopkins University. Previously, he was the Robert K. Royce Distinguished Professor and Chief of Urologic Surgery at Barnes-Jewish Hospital, the Siteman Cancer Center, and Washington University School of Medicine in St. Louis, Missouri. Professor Andriole received his medical degree from Jefferson Medical College in Philadelphia, Pennsylvania. He completed urology residency at Brigham and Women's Hospital and Harvard Medical School, Boston, MA. He then received specialty training in Urologic Oncology at the National Cancer Institute in Bethesda, Maryland. Professor Andriole has over 35 years of consistent contributions in caring for men with prostate cancer and in prostate cancer prevention, screening and treatment research. He has contributed more than 450 peer-reviewed publications and has served on the editorial boards of several prestigious medical journals. He has been Chairman of the Prostate Committee of the National Cancer Institute's Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial; Chairman of the Prostate Committee for the Society of Urologic Oncology Clinical Trials Consortium; and Chairman of the Steering Committee of the REDUCE International Prostate Cancer Prevention Trial. Professor Andriole has been the recipient of numerous awards including the outstanding achievement award from the Urologic Oncology Branch of the National Cancer Institute, the Distinguished Clinician Award from Washington University in St. Louis and the Richard Williams Award for Prostate Cancer Research Excellence from the American Urologic Association Urology Care Foundation. Reported Earnings • Jun 02
First quarter 2023 earnings released First quarter 2023 results: Net loss: kr7.81m (loss widened 41% from 1Q 2022). Annonce • May 13
Prostatype Genomics AB (publ) has completed a Follow-on Equity Offering in the amount of SEK 17.787846 million. Prostatype Genomics AB (publ) has completed a Follow-on Equity Offering in the amount of SEK 17.787846 million.
Security Name: Shares
Security Type: Common Stock
Securities Offered: 71,151,384
Price\Range: SEK 0.25
Transaction Features: Rights Offering Annonce • May 06
Prostatype Genomics AB Appoints Professor Gerald Andriole as Chief Medical Officer Prostatype Genomics AB announced that Professor Gerald Andriole has been appointed as global Chief Medical Officer at Prostatype Genomics. With more than 35 years in urology, Professor Andriole brings a wealth of experience and expertise to Prostatype Genomics as the company works towards commercializing the Prostatype® test in the United States and globally. Gerald L. Andriole, Jr., MD, was most recently Professor in the Department of Urology and Director of the Brady Urological Institute in the National Capital Region of Johns Hopkins University. Previously, he was the Robert K. Royce Distinguished Professor and Chief of Urologic Surgery at Barnes-Jewish Hospital, the Siteman Cancer Center, and Washington University School of Medicine in St. Louis, Missouri. Professor Andriole received his medical degree from Jefferson Medical College in Philadelphia, Pennsylvania. He completed urology residency at Brigham and Women's Hospital and Harvard Medical School, Boston, MA. He then received specialty training in Urologic Oncology at the National Cancer Institute in Bethesda, Maryland. Professor Andriole has over 35 years of consistent contributions in caring for men with prostate cancer and in prostate cancer prevention, screening and treatment research. He has contributed more than 450 peer-reviewed publications and has served on the editorial boards of several prestigious medical journals. He has been Chairman of the Prostate Committee of the National Cancer Institute's Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial; Chairman of the Prostate Committee for the Society of Urologic Oncology Clinical Trials Consortium; and Chairman of the Steering Committee of the REDUCE International Prostate Cancer Prevention Trial. Reported Earnings • Feb 19
Full year 2022 earnings released: kr1.27 loss per share (vs kr1.11 loss in FY 2021) Full year 2022 results: kr1.27 loss per share (further deteriorated from kr1.11 loss in FY 2021). Net loss: kr29.1m (loss widened 86% from FY 2021). Annonce • Feb 17
Prostatype Genomics AB (publ) to Report Fiscal Year 2022 Results on May 04, 2023 Prostatype Genomics AB (publ) announced that they will report fiscal year 2022 results on May 04, 2023 Annonce • Jan 12
Prostatype Genomics Appoints Steven Gaal as President Prostatype Genomics AB (publ) has recruited Steven Gaal to the role of President of the company's wholly owned subsidiary, Prostatype Genomics Inc. Steven's task will be to establish and launch Prostatype®, the company's genomic test to assess the aggressiveness of prostate cancer in individual patients, in the US market. Steven has over 18 years of experience from leading positions in the sale of cancer diagnostic tools and services and begins his employment with Prostatype Genomics Inc. effective immediately. Steven comes to Prostatype Genomics Inc. with extensive experience in genomic testing. Steven has held positions in both early stage companies as well as established companies. He has held senior leadership positions with USLABS (acquired by LabCorp), P4Diagnostix and most recently SkylineDx. As VP of Sales at MDxHealth Steven was instrumental in the launch of ConfirmMDx for Prostate Cancer and SelectMDx for Prostate Cancer to US based Urologists. Reported Earnings • Aug 19
Second quarter 2022 earnings released Second quarter 2022 results: Net loss: kr7.39m (loss widened 213% from 2Q 2021). Over the next year, revenue is forecast to grow 1,278%, compared to a 218% growth forecast for the Biotechs industry in Sweden. Board Change • Jul 31
High number of new directors Director Mattias Prage was the last director to join the board, commencing their role in 2022. Reported Earnings • May 14
First quarter 2022 earnings released First quarter 2022 results: Net loss: kr5.56m (loss widened 62% from 1Q 2021). Over the next year, revenue is forecast to grow 603%, compared to a 1,492% growth forecast for the industry in Sweden. Board Change • Apr 27
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. 1 highly experienced director. Independent Director Hakan Englund was the last director to join the board, commencing their role in 2019. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Annonce • Feb 25
Prostatype Genomics AB (publ) to Report Q4, 2022 Results on Feb 16, 2023 Prostatype Genomics AB (publ) announced that they will report Q4, 2022 results on Feb 16, 2023 Board Change • Feb 02
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. 1 highly experienced director. Independent Director Hakan Englund was the last director to join the board, commencing their role in 2019. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Recent Insider Transactions • Dec 08
CEO & MD recently bought kr72k worth of stock On the 6th of December, Fredrik Persson bought around 8k shares on-market at roughly kr9.01 per share. In the last 3 months, there was an even bigger purchase from another insider worth kr108k. Fredrik has been a buyer over the last 12 months, purchasing a net total of kr255k worth in shares. Recent Insider Transactions • Nov 24
Insider recently bought kr108k worth of stock On the 22nd of November, Håkan Englund bought around 10k shares on-market at roughly kr10.83 per share. This was the largest purchase by an insider in the last 3 months. Insiders have collectively bought kr324k more in shares than they have sold in the last 12 months. Reported Earnings • Nov 19
Third quarter 2021 earnings released Third quarter 2021 results: Net loss: kr3.66m (loss narrowed 23% from 3Q 2020). Reported Earnings • Aug 21
Second quarter 2021 earnings released: kr0.18 loss per share (vs kr0.42 loss in 2Q 2020) The company reported a decent second quarter result with reduced losses and improved control over expenses, although revenues were weaker. Second quarter 2021 results: Revenue: kr549.0k (down 50% from 2Q 2020). Net loss: kr2.36m (loss narrowed 51% from 2Q 2020). 